Analysis of 60 immuno-oncology genes in melanoma patients revealed that higher SIRPα expression in tumor cells correlated with better responses to anti-PD-1 therapy and improved patient outcomes, contrasting with its traditional immunosuppressive role in macrophages. Here, SIRPA is linked to neoplasm.